110 related articles for article (PubMed ID: 7981389)
1. Parametric approaches to quality-adjusted survival analysis. International Breast Cancer Study Group.
Cole BF; Gelber RD; Anderson KM
Biometrics; 1994 Sep; 50(3):621-31. PubMed ID: 7981389
[TBL] [Abstract][Full Text] [Related]
2. Quality of life in clinical trials of adjuvant therapies. International Breast Cancer Study Group (formerly Ludwig Group).
Gelber RD; Goldhirsch A; Hürny C; Bernhard J; Simes RJ
J Natl Cancer Inst Monogr; 1992; (11):127-35. PubMed ID: 1385719
[TBL] [Abstract][Full Text] [Related]
3. Joint models for multivariate longitudinal and multivariate survival data.
Chi YY; Ibrahim JG
Biometrics; 2006 Jun; 62(2):432-45. PubMed ID: 16918907
[TBL] [Abstract][Full Text] [Related]
4. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
5. Parametric regression on cumulative incidence function.
Jeong JH; Fine JP
Biostatistics; 2007 Apr; 8(2):184-96. PubMed ID: 16636138
[TBL] [Abstract][Full Text] [Related]
6. Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. International Breast Cancer Study Group.
Gelber RD; Goldhirsch A; Cole BF
Control Clin Trials; 1993 Dec; 14(6):485-99. PubMed ID: 8119064
[TBL] [Abstract][Full Text] [Related]
7. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study.
Efficace F; Therasse P; Piccart MJ; Coens C; van Steen K; Welnicka-Jaskiewicz M; Cufer T; Dyczka J; Lichinitser M; Shepherd L; de Haes H; Sprangers MA; Bottomley A
J Clin Oncol; 2004 Aug; 22(16):3381-8. PubMed ID: 15310784
[TBL] [Abstract][Full Text] [Related]
9. A quality-of-life-oriented endpoint for comparing therapies.
Gelber RD; Gelman RS; Goldhirsch A
Biometrics; 1989 Sep; 45(3):781-95. PubMed ID: 2790121
[TBL] [Abstract][Full Text] [Related]
10. A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer.
Cole BF; Gelber RD; Gelber S; Mukhopadhyay P
J Biopharm Stat; 2004 Feb; 14(1):111-24. PubMed ID: 15027503
[TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy for patients with high-risk breast cancer: a clinical and economic assessment using a quality-adjusted survival analysis.
Marino P; Roché H; Moatti JP;
Am J Clin Oncol; 2008 Apr; 31(2):117-24. PubMed ID: 18391594
[TBL] [Abstract][Full Text] [Related]
12. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases.
Komoike Y; Akiyama F; Iino Y; Ikeda T; Akashi-Tanaka S; Ohsumi S; Kusama M; Sano M; Shin E; Suemasu K; Sonoo H; Taguchi T; Nishi T; Nishimura R; Haga S; Mise K; Kinoshita T; Murakami S; Yoshimoto M; Tsukuma H; Inaji H
Cancer; 2006 Jan; 106(1):35-41. PubMed ID: 16333848
[TBL] [Abstract][Full Text] [Related]
13. Extended follow-up and spatial analysis of the American Cancer Society study linking particulate air pollution and mortality.
Krewski D; Jerrett M; Burnett RT; Ma R; Hughes E; Shi Y; Turner MC; Pope CA; Thurston G; Calle EE; Thun MJ; Beckerman B; DeLuca P; Finkelstein N; Ito K; Moore DK; Newbold KB; Ramsay T; Ross Z; Shin H; Tempalski B
Res Rep Health Eff Inst; 2009 May; (140):5-114; discussion 115-36. PubMed ID: 19627030
[TBL] [Abstract][Full Text] [Related]
14. Decision analysis of tamoxifen for the prevention of invasive breast cancer.
Grann VR; Sundararajan V; Jacobson JS; Whang W; Heitjan DF; Antman KH; Neugut AI
Cancer J; 2000; 6(3):169-78. PubMed ID: 10882333
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
16. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
17. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
19. Artificial neural network for the joint modelling of discrete cause-specific hazards.
Biganzoli EM; Boracchi P; Ambrogi F; Marubini E
Artif Intell Med; 2006 Jun; 37(2):119-30. PubMed ID: 16730963
[TBL] [Abstract][Full Text] [Related]
20. Regression analysis of interval-censored survival data with covariates using log-linear models.
Kim DK
Biometrics; 1997 Dec; 53(4):1274-83. PubMed ID: 9423249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
